HIV and Tuberculosis

1.Overview of the HIV-associated tuberculosis epidemicContance A. Benson
2.Epidemiology of Drug-susceptible, Drug-resistant Tuberculosis and HIV in AfricaKogieleum Naidoo and Nikita Naicker
3.Modelling the HIV-associated TB epidemic and the impact of interventions aimed at epidemic controlP.J. Dodd, C. Pretorius, B.G. Williams
4.Immune Responses to Mycobacterium tuberculosis and the impact of HIV infectionCatherine Riou, Cari Stek, Elsa Du Bruyn
5.Clinical Manifestations of HIV-associated tuberculosis in adultsSean Wasserman, David Barr, Graeme Meintjes
6.The tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS)Irini Sereti, Gregory P. Bisson, Graeme Meintjes
7.Diagnosis of HIV-associated tuberculosisAndrew Kerkhoff, Adithya Cattamanchi
8.Recent advances in the treatment of latent tuberculosis infection among adults living with HIV infectionApril C. Pettit, Timothy R. Sterling
9.Treatment of drug-sensitive tuberculosis in persons with HIVAlice K. Pau, Safia Kuriakose, Kelly E. Dooley, Gary Maartens
10.Drug-resistant TB and HIVSara C. Auld, Neel R. Gandhi, James C.M. Brust
11.Co-treatment of tuberculosis and HIV: pharmacologic considerationsEthel D. Weld, Alice K. Pau, Kelly E. Dooley
12.HIV and TB in childrenTonya Arscott-Mills, Ben Marais, Andrew Steenhoff
13.Neurological TB in HIVLouise Bovijn, Regan Solomons, Suzaan Marais

Irini Sereti is a Senior Investigator and Chief of the HIV Pathogenesis Section at the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health in Bethesda, MD, USA. She is an Infectious Diseases trained physician with expertise in HIV and opportunistic infections including TB, doing translational research at the NIH Clinical Center where she sees patients enrolled in her clinical protocols while also conducting related laboratory research. The main focus of her research is study of people with HIV and advanced disease (low CD4 counts) and opportunistic infections, including TB, in the current antiretroviral area. She also studies inflammation in HIV infection both acutely after antiretroviral therapy initiation in the form of IRIS, but also chronically after suppression of HIV viremia, and has published papers on mycobacterial IRIS pathogenesis and imaging modalities. Her studies aim to better understand pathogenesis of HIV and severe CD4 lymphopenia with the goal to improve management of patients with late presentation to care.

Graeme Meintjes is a Professor of Medicine, Wellcome Fellow and SARChI Chair of Poverty-related Infections at the University of Cape Town. He is an Infectious Diseases Physician who undertakes consultant clinical work at Khayelitsha and Groote Schuur Hospitals. His research focuses on the clinical conditions affecting patients with advanced HIV disease including disseminated HIV-associated tuberculosis, the tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) and cryptococcal meningitis. His group also investigates drug-resistant tuberculosis. He has been the PI or local PI of several clinical trials and conducts observational cohort studies that address questions related to disease pathogenesis. Recently, he was PI of the EDCTP-funded PredART trial that demonstrated that prednisone was effective and safe for the prevention of TB-IRIS in